A “time machine” that Purdue University engineers designed to observe pancreatic cancer behavior over time suggests a new drug testing approach that could help scientists better catch resistance. Read more . . .
With more than 10 years of clinical and genomic data from the COMPASS trial, OICR-supported researchers have recently discovered a new, simplified way to match patients with the most appropriate treatment for their disease by measuring the expression of two genes, GATA6 and Keratin 5. Their discovery was recently published in Clinical Cancer Research. Read more…
Due to such a low incidence of this disease, screening the whole population is neither practical nor appropriate. Current diagnostic markers are very expensive per cancer and are challenged by cost and morbidity associated with invasive testing. Read more . . .
We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2rγ–IL4rα and IL2rγ–IL13rα1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2…
The primary outcome measure was efficacy, defined by 2‐year overall survival (OS). Secondary outcomes were incidence of any grade 3/4 toxicity and 1‐year OS. Read more . . .
This was a major advancement for this patient subset, explained Teresa Marcarulla, MD, a gastrointestinal medical oncologist at the Vall d’Hebron Institute of Oncology. Watch here. . .
Panelists: Edward Kim, MD, University of California Davis; John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center; Paul Oberstein, MD, NYU Langone Perlmutter Cancer Center; Allyson Ocean, MD, Weill Cornell Medical College; Shubham Pant, MD, The University of Texas MD Anderson Cancer Center. Watch here . . .
“The findings could point to a therapeutic target or an important prognostic biomarker,” said George Prendergast, PhD, President and CEO of the Lankenau Institute for Medical Research (LIMR) of Main Line Health … Read more . . .